Form 4: ALX Oncology Executive Granted 140K Stock Options

ALX Oncology Holdings Inc. SVP of Finance and CAO, Shelly Pinto, was granted 140,000 employee stock options with an exercise price of $1.7.

Summary

• Shelly Pinto, SVP, Finance and CAO of ALX Oncology Holdings Inc. (ALXO), acquired 140,000 employee stock options.
• The transaction date for the option grant was October 14, 2025.
• Each option has an exercise price of $1.7 per share.
• The options grant the right to buy 140,000 shares of ALX Oncology Holdings Inc. Common Stock.
• The options have an expiration date of October 14, 2035.
• One-third of the shares subject to the option will vest on April 30, 2026.
• The remaining two-thirds of the option will vest on October 31, 2026.
• Following this transaction, Shelly Pinto beneficially owns 140,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive as the grant of stock options aligns executive incentives with shareholder interests, which is generally viewed favorably. However, it is a routine compensation event and does not indicate significant operational or financial news.

Positives

• The grant of stock options aligns the interests of a key executive, Shelly Pinto, with those of shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a long-term incentive for the executive.

Future Outlook

The vesting schedule for the granted stock options indicates future potential ownership for the executive, contingent on continued employment and company performance, aligning long-term incentives.

Industry Context

The grant of employee stock options to a senior executive is a common practice in the biotechnology and pharmaceutical industries, including companies like ALX Oncology, to attract, retain, and incentivize key talent. This compensation structure is widely used to align executive performance with shareholder value creation, particularly in growth-oriented sectors where long-term development cycles are prevalent.

Comparison to Industry Standards

• The grant of stock options to a Senior Vice President of Finance and CAO is a standard component of executive compensation packages across the biotech and broader corporate landscape, comparable to practices at companies such as Amgen, Gilead Sciences, or Moderna, which frequently utilize equity-based incentives.
• The exercise price of $1.7, likely the market price on the grant date, is typical for at-the-money options grants, ensuring the executive benefits from future stock price appreciation.
• The 10-year expiration period for the options is a common duration for employee stock options, providing a substantial window for value realization.

Stakeholder Impact

• Shareholders: The grant of options aims to align management's financial interests with shareholder value creation, potentially leading to improved long-term performance.
• Employees (Executive): Shelly Pinto receives a significant equity incentive, enhancing her compensation package and providing a direct stake in the company's future success.

Next Steps

• Vesting of one-third of the options on April 30, 2026.
• Vesting of the remaining two-thirds of the options on October 31, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (stock option grant) and does not contain information that would fundamentally alter the investment thesis for ALX Oncology Holdings Inc. While the grant aligns management incentives, it is not indicative of new operational performance, financial results, or strategic shifts that would warrant a 'buy' or 'sell' recommendation based solely on this filing. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive corporate updates.

Keywords

ALX Oncology Holdings Inc., ALXO, Shelly Pinto, Stock Options, Executive Compensation, Insider Transaction, Form 4, Equity Grant